Results of two consecutive treatment protocols in Polish children with acute lymphoblastic leukemia
Joanna Zawitkowska, Monika Lejman, Michał Romiszewski, Michał Matysiak, Magdalena Ćwiklińska, Walentyna Balwierz, Joanna Owoc‐Lempach, Bernarda Kazanowska, Katarzyna Derwich, Jacek Wachowiak, Maciej Niedźwiecki, Elżbieta Adamkiewicz-Drożyńska, Joanna Trelińska, Wojciech Młynarski, Andrzej Kołtan, Mariusz Wysocki, Renata Tomaszewska, Tomasz Szczepański, Marcin Płonowski, Maryna Krawczuk‐Rybak, Justyna Urbańska-Rakus, Katarzyna Machnik, Tomasz Ociepa, Tomasz Urasiński, Agnieszka Mizia‐Malarz, Grażyna Sobol, Grażyna Karolczyk, Jerzy Kowalczyk
Abstract
The aim of the study was to retrospectively compare the effectiveness of the ALL IC-BFM 2002 and ALL IC-BFM 2009 protocols and the distribution of risk groups by the two protocols after minimal residual disease (MRD) measurement as well as its impact on survival. We reviewed the medical records of 3248 patients aged 1-18 years with newly diagnosed ALL who were treated in 14 hemato-oncological centers between 2002 and 2018 in Poland. The overall survival (OS) of 1872 children with ALL treated with the ALL IC 2002 protocol was 84% after 3 years, whereas the OS of 1376 children with ALL treated with the ALL IC 2009 protocol was 87% (P < 0.001). The corresponding event-free survival rates were 82% and 84% (P = 0.006). Our study shows that the ALL IC-BFM 2009 protocol improved the results of children with ALL compared to the ALL IC-BFM 2002 protocol in Poland. This analysis confirms that MRD marrow assessment on day 15 of treatment by FCM-MRD is an important predictive factor.